Business News

Cancer Treatment Application of the Aethlon Hemopurifier(R) Published in Journal of Translational Medicine

2008-07-24 06:00:00

Cancer Treatment Application of the Aethlon Hemopurifier(R) Published in Journal of Translational Medicine

SAN DIEGO–(EMWNews)–Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that a peer reviewed

scientific paper coauthored by Aethlon researchers has been published in

the Journal of Translational Medicine. The paper entitled, Exosomes

as a Tumor Immune Escape Mechanism: Possible Therapeutic Implications

discusses the mechanism by which exosomes released by cancerous tumors

are able to kill off immune cells in cancer patients. The paper further

discusses the novel therapeutic approach of the Aethlon Hemopurifier®

to capture and inhibit the spread of such immunosuppressive exosomes in

cancer patients. The abstract and complete article are available to be

accessed online at: www.translational-medicine.com/content/6/1/37.

As we continue to progress the infectious

disease applications of our Hemopurifier®, the

Journal of Translational Medicine publication recognizes and reinforces

the additional potential of the Hemopurifier®

within the $43 billion cancer therapy market,

stated Aethlon Chairman and CEO, James A. Joyce. We

thank the numerous researchers who participated in coauthoring the paper

with our research team, concluded Joyce.

Aethlon previously disclosed that researchers discovered that the

Hemopurifier® is effective in capturing

exosomes that are released by solid tumors, lymphomas, and leukemia.

Exosomes induce T-cell apoptosis (programmed cell death), and block

T-cell signaling, proliferation, and cytokine production. High

concentrations of circulating exosomes correlate with reduced T-cell

production and tumor progression in cancer patients. In studies led by

Dr. Douglas Taylor at the University of Louisville, 60% of circulating

exosomes were removed from the blood of ovarian cancer patients during

first pass (approximately 10-minutes) through a small scale Hemopurifier®.

The capture data was consistent over the course of five different in

vitro blood studies. The ability to reduce circulating exosomes would

likely reverse immune suppression and increase patient responsiveness to

both immunotherapy and chemotherapy. Dr. Taylor is a recognized

authority on the causative effects of immune suppression in cancer

patients. He is credited with the initial characterization of exosomes

and is the leading peer reviewed author on the subject.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier®,

a first-in-class medical device designed to treat infectious disease.

The Hemopurifier® provides real-time

therapeutic filtration of infectious viruses and immunosuppressive

particles, and is positioned to address the treatment of drug and

vaccine resistant viruses. Additionally, the device holds promise in

cancer care, as research studies have verified the Hemopurifier®

is able to capture immunosuppressive particles secreted by tumors. The

Hemopurifier® is designed to act both as a

stand-alone therapeutic, and as an adjunct treatment to enhance clinical

benefit of established therapies. Pre-clinical studies conducted by

researchers representing leading government and non-government health

organizations both in the United States and abroad have documented the

effectiveness of the Hemopurifier® in

capturing from circulation the viruses that constitute pandemic threats,

including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever

(DHF) from circulation. The company is conducting studies to support the

use of the Hemopurifier® as a broad-spectrum

treatment countermeasure against bioterror threats, including Smallpox,

and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and

commercialization initiatives in the United States are presently focused

on bioterror threats, while international initiatives are directed

toward naturally evolving pandemic threats, and chronic infectious

disease conditions including the Human Immunodeficiency Virus (HIV) and

Hepatitis-C (HCV). Aethlon demonstrated the safety of the Hemopurifier®

in a 24-treatment human study at the Apollo Hospital in Delhi, India,

and is currently conducting further human studies at the Fortis

Hospital, also located in Delhi. The company has submitted an

investigational device exemption (IDE) to the U.S. Food and Drug

Administration (FDA) to advance the Hemopurifier®

as a broad-spectrum treatment countermeasure against category A

bioterror threats. Additional information regarding Aethlon Medical and

its Hemopurifier®

technology is available online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve

risks and uncertainties. Such forward-looking statements involve

assumptions, known and unknown risks, uncertainties and other factors

which may cause the actual results, performance or achievements of

Aethlon Medical, Inc. to be materially different from any future

results, performance, or achievements expressed or implied by the

forward-looking statements. Such potential risks and

uncertainties include, without limitation, the Companys

ability to raise capital when needed, the Companys

ability to complete the development of its planned products, the ability

of the Company to obtain FDA and other regulatory approvals permitting

the sale of its products, the Companys

ability to manufacture its products and provide its services, the impact

of government regulations, patent protection on the Companys

proprietary technology, product liability exposure, uncertainty of

market acceptance, competition, technological change, and other risk

factors. In such instances, actual results could differ materially as a

result of a variety of factors, including the risks associated with the

effect of changing economic conditions and other risk factors detailed

in the Companys Securities and Exchange

Commission filings.

Aethlon Medical, Inc.
Jeff Richardson, 858-459-7800, x302
Senior

Director, Communications
jrichardson@aethlonmedical.com
or
James

A. Joyce, 858-459-7800, x301
Chairman, CEO
jj@aethlonmedical.com

free cash grants, free grant money, free money, cash grants, scholarships, business grants, foundation grants, government grants, debt grants, consolidation, college tuition, financial aid, medical grants, personal grants, medical bills, unsecured loans, no interest loans, financing, loans, capital, non profit organizations

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions





























Jordan Taylor

Jordan Taylor is Sr. Editor & writer from San Diego, CA. With over 20 years and 2650+ articles edited rest assured your Press Release will see traction.

Related Articles

Back to top button